Unveiling PIK3CA mutation: a prognostic beacon in endometrial carcinoma and its immune implications
Translational Cancer Research · 2025-10 · 14 (10) · 6469-6482
DOI: 10.21037/tcr-2025-704 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Cancer Research, 2025-10. Verfasst von Shuai Cao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, Tianjin Cancer Hospital Airport Hospital, Tianjin, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Endometrial carcinoma (EC) is a prevalent gynecological malignancy with diverse genetic underpinnings. This study aimed to elucidate the prognostic significance of genetic mutations, particularly PIK3CA, and their impact on immune landscape and therapeutic outcomes in EC.
Methods
Clinical and RNAseq data were acquired from cBioPortal and The Cancer Genome Atlas (TCGA). These data were utilized for prognostic analysis. Immune landscape analysis using single sample Gene Set Enrichment Analysis (ssGSEA) revealed enhanced infiltration of immune cells in PIK3CA-mutated samples. A PIK3CA-related risk model was constructed using least absolute shrinkage and selection operator (LASSO) regression. A nomogram was used the results derived from Cox univariate regression analysis.
Results
We identified PIK3CA mutation significantly correlating with improved overall survival (OS). Immune landscape analysis suggested an activated immune state. Differential expression analysis identified 50 differentially expressed genes (DEGs), predominantly upregulated in the mutant group, with enrichment in immune-related pathways, particularly B cell functions. Furthermore, PIK3CA mutation was associated with higher tumor mutational burden (TMB) and distinct immune profiles, potentially enhancing responsiveness to immunotherapy. A PIK3CA-related risk model identified three key genes (IGHA1, CRABP1, and SST) associated with survival outcomes. Finally, the nomogram was helpful to predict the prognosis of patients with EC.
Conclusions
Our study highlighted the potential of PIK3CA mutation as a biomarker for stratifying EC patients and tailoring therapeutic strategies, particularly in the context of immune checkpoint inhibitors. Future research should focus on elucidating the mechanistic role of PIK3CA in EC pathogenesis and its interaction with the tumor microenvironment (TME) to optimize patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiotherapy, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.
- Hepatobiliary and Vascular Surgery, People's Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Clinical Laboratory, People's Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Clinical Laboratory, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.
- Center for Precision Cancer Medicine and Translational Research, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.
- Clinical Research Management Department, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.
ORCID-Profile: Dongmei Han, Hao Jin
Zitieren
APA
Cao, S., Zhao, Y., Zhang, L., Zhuang, J., Jia, P., Han, D., Jin, H., & Xu, L. (2025). Unveiling PIK3CA mutation: a prognostic beacon in endometrial carcinoma and its immune implications. Translational Cancer Research, 14(10), 6469-6482. https://doi.org/10.21037/tcr-2025-704
Vancouver
Cao S, Zhao Y, Zhang L, Zhuang J, Jia P, Han D, et al. Unveiling PIK3CA mutation: a prognostic beacon in endometrial carcinoma and its immune implications. Translational Cancer Research. 2025;14(10):6469-6482. doi:10.21037/tcr-2025-704
BibTeX
@article{Cao2025,
author = {Cao, Shuai and Zhao, Yucheng and Zhang, Lu and Zhuang, Junhong and Jia, Peiqi and Han, Dongmei and Jin, Hao and Xu, Liming},
title = {Unveiling PIK3CA mutation: a prognostic beacon in endometrial carcinoma and its immune implications},
journal = {Translational Cancer Research},
year = {2025},
volume = {14},
number = {10},
pages = {6469--6482},
doi = {10.21037/tcr-2025-704}
}
EUVIMED